載入中
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
一般交易時段
US$1.715
−US$0.015 · -0.87%
盤中時間採用ET。市場資料可能有所延遲。
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
日內區間
目前US$1.715
52週區間
目前US$1.715
盤中時間採用ET。市場資料可能有所延遲。
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid. This innovative non-viral immunotherapy is being developed to treat non-muscle invasive bladder cancer in patients diagnosed with carcinoma-in-situ (Cis) who have shown no improvement after Bacillus Calmette-Guérin therapy. The company was established in 2023 and is headquartered in Saint-Laurent, Canada.
日內區間
目前US$1.715
52週區間
目前US$1.715
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 研究與開發 | 9448萬 USD | 3831.5萬 USD | 1645.8萬 USD | 1546.7萬 USD | 1246.2萬 USD |
| 銷售、一般及管理費用 | 2868.5萬 USD | 2398.2萬 USD | 847萬 USD | 326萬 USD | 315.5萬 USD |
| 營業費用 | 1.23億 USD | 6229.7萬 USD | 2606萬 USD | 1942.7萬 USD | 1587萬 USD |
| 利息收入 | 942.6萬 USD | 1041.3萬 USD | 111.7萬 USD | 12.9萬 USD | 2.5萬 USD |
| 利息支出 | 299.4萬 USD | 279.8萬 USD | 495.3萬 USD | 142.3萬 USD | 502.4萬 USD |
| 折舊和攤銷 | 50.9萬 USD | 32.3萬 USD | 17.5萬 USD | 23.8萬 USD | 27.2萬 USD |
| 營業利益 | −1.23億 USD | −6229.7萬 USD | −2606萬 USD | −1942.7萬 USD | −1587萬 USD |
| 淨利 | −1.17億 USD | −5514.2萬 USD | −9991.7萬 USD | −2446.2萬 USD | −2344.1萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
